source
- Coultreon Biopharma secures $125M to advance SIK inhibitor for autoimmune diseasesCoultreon Biopharma announced a $125 million financing round on April 28, 2026, backed by major biotech investors from the United States and Europe. The capital will be used to develop a new appro…
- Boehringer's obesity injection shows 17% weight loss after 18 months, comparable to Wegovy but below ZepboundBoehringer Ingelheim, together with Zealand, released data from a late‑stage study of its experimental obesity injection. The trial followed patients for roughly a year and a half. Participants on…